<DOC>
	<DOCNO>NCT00003852</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow patient tolerate high dos chemotherapy kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy peripheral stem cell transplantation treat patient germ cell tumor respond previous chemotherapy .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Treating Patients With Germ Cell Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine complete response rate ( chemotherapy complete response , pathological complete response , surgical complete response ) intensive chemotherapy autologous peripheral blood stem cell support patient cisplatin resistant germ cell tumor . II . Determine duration complete response survival patient therapy . III . Determine toxic effect regimen patient . IV . Determine pharmacokinetics regimen relationship pharmacokinetics , nature duration response treatment , toxic effect patient . OUTLINE : This open label , multicenter study . Patients receive epirubicin IV 15 minute paclitaxel IV 3 hour day 1 , filgrastim ( G-CSF ) subcutaneously ( SQ ) day 5-14 . Peripheral blood stem cell ( PBSC ) collect day 13 14 . This course repeat begin day 15 . Patients undergo three part intensification regimen . Part I : Patients receive cyclophosphamide IV thiotepa IV continuous infusion day 34 35 . PBSC reinfused day 38 , G-CSF SQ administer day 39 blood cell count recover . Part II : Patients receive etoposide IV 2 hour , ifosfamide IV 4 hour , carboplatin IV 6 hour day 62-66 . PBSC reinfused day 70 , eventually G-CSF begin day 71 . Part III : Patients receive etoposide , ifosfamide , carboplatin day 90-94 part II . PBSC reinfused day 98 eventually G-CSF begin day 99 . Patients follow every month first year , every 2 month second year , every 6 month third fourth year , annually thereafter . PROJECTED ACCRUAL : A total 45 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven germ cell tumor Seminoma nondysgerminoma origin Gonadal ( testicular ovarian ) OR Extragonadal OR Retroperitoneal OR Primitive mediastinal AFP elevate and/or HCG great 200 mIU/mL No grow teratoma Refractory disease treatment line Refractory disease define elevation AFP and/or HCG chemotherapy Refractory treatment line consist one conventional dose cisplatin ( dose intensity great 33 mg/m2/week ) OR least 1 month since last course chemotherapy without increase size measurable lesion OR Received 2 regimen conventional chemotherapy , typically follow : Bleomycin , etoposide , cisplatin : 34 courses* OR Etoposide cisplatin : 4 courses* AND Vinblastine , etoposide , ifosfamide , cisplatin : 4 course 3 week regimen ( standard salvage chemotherapy ) * * Unless patient could treat first line conventional treatment OR first salvage conventional treatment especially patient could treat T93 good prognosis protocol T93 bad prognosis protocol IT94 protocol Bidimensionally measurable disease OR Significant elevation tumor marker : HCG , free betaHCG , AFP OR Evaluable disease plus increase tumor marker No germ cell CNS tumor clinically significant CNS metastases PATIENT CHARACTERISTICS : Age : Over 15 Performance status : ECOG 02 Life expectancy : Greater 3 month Hematopoietic : WBC great 3,000/mm3 AND Platelet count great 150,000/mm3 Hepatic : Bilirubin le 1.5 time normal SGOT/SGPT le 2 time upper limit normal ( ULN ) Alkaline phosphatase less 2 time ULN Gamma glutamyl transferase le 2 time ULN Renal : Creatinine le 1.4 mg/dL Creatine clearance great 60 mL/min Cardiovascular : No cardiac insufficiency LVEF least 50 % Other : HIV negative No malignancy except basal cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior intensive chemotherapy stem cell support Endocrine therapy : Not specify Radiotherapy : Prior prophylactic anterior irradiation diaphragm stage I seminoma allow Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>childhood germ cell tumor</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>extragonadal germ cell tumor</keyword>
</DOC>